PMID- 22357441
OWN - NLM
STAT- MEDLINE
DCOM- 20120720
LR  - 20201216
IS  - 1879-0844 (Electronic)
IS  - 1388-9842 (Linking)
VI  - 14
IP  - 4
DP  - 2012 Apr
TI  - alpha-Defensins and outcome in patients with chronic heart failure.
PG  - 387-94
LID - 10.1093/eurjhf/hfs021 [doi]
AB  - AIM: alpha-Defensins are part of the innate immune system. Low-grade inflammation 
      seems to play a crucial role in development and progression of chronic heart 
      failure (CHF). The aims of the present study were to compare plasma levels of 
      alpha-defensins in CHF patients and healthy controls and to examine the predictive 
      ability of alpha-defensins, alone and combined with N-terminal pro brain natriuretic 
      peptide (NT-proBNP), with respect to all-cause mortality. METHODS AND RESULTS: In 
      a prospective observational study lasting 2.6 years we examined the prognostic 
      value of plasma alpha-defensins with respect to mortality in 194 CHF patients, and 
      compared plasma levels with those of 98 age-matched healthy controls. alpha-Defensin 
      levels were twice as high among CHF patients in New York Heart Association (NYHA) 
      functional class III-IV than in patients in NYHA class I-II and healthy controls 
      (P = 0.001). The absolute increase in risk of mortality for patients with 
      alpha-defensin levels in the upper tertile vs. the lowest tertile was 30% (P = 
      0.002). After adjusting for potential confounders including NT-proBNP, plasma 
      alpha-defensins remained independently associated with an increased risk of all-cause 
      mortality (hazard ratio 1.65, 95% confidence interval 1.19-2.28, P = 0.002) per 1 
      standard deviation increment in Ln (natural logarithm)-transformed alpha-defensin 
      values. The combination of high alpha-defensins and NT-proBNP levels provided 
      incremental prognostic information independent of well-known prognostic 
      biomarkers in heart failure. CONCLUSION: Plasma alpha-defensins appear to have 
      prognostic information regarding mortality among patients with CHF and seem to 
      provide incremental information to established clinical risk markers.
FAU - Christensen, Heidi M
AU  - Christensen HM
AD  - Department of Cardiology, Herlev University Hospital, Herlev Ringvej 75, Herlev, 
      Denmark. heidichristensen@dadlnet.dk
FAU - Frystyk, Jan
AU  - Frystyk J
FAU - Faber, Jens
AU  - Faber J
FAU - Schou, Morten
AU  - Schou M
FAU - Flyvbjerg, Allan
AU  - Flyvbjerg A
FAU - Hildebrandt, Per
AU  - Hildebrandt P
FAU - Raymond, Ilan
AU  - Raymond I
FAU - Klausen, Tobias W
AU  - Klausen TW
FAU - Kistorp, Caroline
AU  - Kistorp C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120222
PL  - England
TA  - Eur J Heart Fail
JT  - European journal of heart failure
JID - 100887595
RN  - 0 (Biomarkers)
RN  - 0 (Peptide Fragments)
RN  - 0 (alpha-Defensins)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Aged
MH  - Analysis of Variance
MH  - Biomarkers
MH  - C-Reactive Protein
MH  - Case-Control Studies
MH  - Confidence Intervals
MH  - Denmark
MH  - Female
MH  - Heart Failure/blood/mortality/*pathology
MH  - Humans
MH  - Inflammation/blood/*pathology
MH  - Linear Models
MH  - Male
MH  - Natriuretic Peptide, Brain/*blood
MH  - Peptide Fragments/*blood
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Prospective Studies
MH  - Statistics as Topic
MH  - Statistics, Nonparametric
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - alpha-Defensins/*blood
EDAT- 2012/02/24 06:00
MHDA- 2012/07/21 06:00
CRDT- 2012/02/24 06:00
PHST- 2012/02/24 06:00 [entrez]
PHST- 2012/02/24 06:00 [pubmed]
PHST- 2012/07/21 06:00 [medline]
AID - hfs021 [pii]
AID - 10.1093/eurjhf/hfs021 [doi]
PST - ppublish
SO  - Eur J Heart Fail. 2012 Apr;14(4):387-94. doi: 10.1093/eurjhf/hfs021. Epub 2012 
      Feb 22.